R Virtanen

1.3k total citations
26 papers, 1.0k citations indexed

About

R Virtanen is a scholar working on Anesthesiology and Pain Medicine, Molecular Biology and Small Animals. According to data from OpenAlex, R Virtanen has authored 26 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Anesthesiology and Pain Medicine, 7 papers in Molecular Biology and 6 papers in Small Animals. Recurrent topics in R Virtanen's work include Anesthesia and Sedative Agents (8 papers), Veterinary Pharmacology and Anesthesia (6 papers) and Receptor Mechanisms and Signaling (5 papers). R Virtanen is often cited by papers focused on Anesthesia and Sedative Agents (8 papers), Veterinary Pharmacology and Anesthesia (6 papers) and Receptor Mechanisms and Signaling (5 papers). R Virtanen collaborates with scholars based in Finland, Cyprus and Sweden. R Virtanen's co-authors include Juha‐Matti Savola, Veijo Saano, E Iisalo, Mika Scheinin, Ewen MacDonald, J Kanto, Antero Kallio, Riku Aantaa, Antti Haapalinna and Harry Scheinin and has published in prestigious journals such as The FASEB Journal, Journal of Pharmacology and Experimental Therapeutics and British Journal of Pharmacology.

In The Last Decade

R Virtanen

26 papers receiving 961 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R Virtanen Finland 18 370 321 289 252 185 26 1.0k
Raimo Virtanen Finland 17 371 1.0× 631 2.0× 466 1.6× 318 1.3× 155 0.8× 30 1.5k
Babette Kögel Germany 19 272 0.7× 361 1.1× 386 1.3× 302 1.2× 252 1.4× 30 1.4k
E E Codd United States 9 860 2.3× 597 1.9× 307 1.1× 200 0.8× 303 1.6× 16 1.8k
Robert B. Raffa United States 11 564 1.5× 403 1.3× 371 1.3× 313 1.2× 265 1.4× 18 1.6k
Kouichiro Minami Japan 24 329 0.9× 331 1.0× 650 2.2× 639 2.5× 107 0.6× 87 1.7k
Ulrich Jahnel Germany 16 164 0.4× 358 1.1× 374 1.3× 409 1.6× 261 1.4× 28 1.3k
Wolfgang Reimann Germany 20 1.1k 2.8× 633 2.0× 1.0k 3.5× 703 2.8× 361 2.0× 38 2.8k
Mme Hélène Schmitt France 10 147 0.4× 78 0.2× 371 1.3× 385 1.5× 86 0.5× 10 951
A. Donald Finck United States 16 60 0.2× 256 0.8× 379 1.3× 225 0.9× 91 0.5× 29 999
F.P. Ludueña United States 11 129 0.3× 130 0.4× 682 2.4× 1.2k 4.6× 138 0.7× 39 2.3k

Countries citing papers authored by R Virtanen

Since Specialization
Citations

This map shows the geographic impact of R Virtanen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Virtanen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Virtanen more than expected).

Fields of papers citing papers by R Virtanen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R Virtanen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Virtanen. The network helps show where R Virtanen may publish in the future.

Co-authorship network of co-authors of R Virtanen

This figure shows the co-authorship network connecting the top 25 collaborators of R Virtanen. A scholar is included among the top collaborators of R Virtanen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R Virtanen. R Virtanen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sallinen, Jukka, Mia Engström, Jyrki Lehtimäki, et al.. (2007). Pharmacological characterization and CNS effects of a novel highly selectiveα2C‐adrenoceptor antagonist JP‐1302. British Journal of Pharmacology. 150(4). 391–402. 84 indexed citations
2.
Pajulo, Olli, Kari Pulkki, Markku Alanen, et al.. (2001). Hyaluronic acid in incision wound fluid: A clinical study with the Cellstick® device in children. Wound Repair and Regeneration. 9(3). 200–204. 6 indexed citations
3.
Jansson, Christian, Jyrki P. Kukkonen, Johnny Näsman, et al.. (1998). Protean agonism at alpha2A-adrenoceptors.. PubMed. 53(5). 963–8. 62 indexed citations
4.
Aantaa, Riku, Antero Kallio, & R Virtanen. (1993). Dexmedetomidine, a novel alpha2-adrenergic agonist. A review of its pharmacodynamic characteristics. Drugs of the Future. 18(1). 49–49. 67 indexed citations
5.
MacDonald, Ewen, Mika Scheinin, Harry Scheinin, & R Virtanen. (1991). Comparison of the behavioral and neurochemical effects of the two optical enantiomers of medetomidine, a selective alpha-2-adrenoceptor agonist.. Journal of Pharmacology and Experimental Therapeutics. 259(2). 848–854. 69 indexed citations
6.
Virtanen, R, Juha‐Matti Savola, & Veijo Saano. (1989). Highly selective and specific antagonism of central and peripheral alpha 2-adrenoceptors by atipamezole.. PubMed. 297. 190–204. 156 indexed citations
7.
Virtanen, R. (1989). Pharmacological profiles of medetomidine and its antagonist, atipamezole.. PubMed. 85. 29–37. 235 indexed citations
8.
MacDonald, Ewen, Antti Haapalinna, R Virtanen, & Risto Lammintausta. (1989). Effects of acute administration of medetomidine on the behaviour, temperature and turnover rates of brain biogenic amines in rodents and reversal of these effects by atipamezole.. PubMed. 85. 77–81. 35 indexed citations
9.
MacDonald, Ewen, Antti Haapalinna, R Virtanen, & Risto Lammintausta. (1988). Medetomidine a highly specific alpha 2 adrenoceptor agonist has potential anxiolytic properties. The FASEB Journal. 2(5). 7366. 2 indexed citations
10.
Virtanen, R. (1986). Pharmacology of detomidine and other alpha 2-adrenoceptor agonists in the brain.. PubMed. 82. 35–46. 23 indexed citations
11.
Scheinin, Mika, R Virtanen, & E Iisalo. (1985). Effect of single and repeated doses of activated charcoal on the pharmacokinetics of doxepin.. PubMed. 23(1). 38–42. 21 indexed citations
12.
Virtanen, R, Heikki Ruskoaho, & Leena Nyman. (1985). Pharmacological evidence for the involvement of alpha‐2 adrenoceptors in the sedative effect of detomidine, a novel sedative‐analgesic. Journal of Veterinary Pharmacology and Therapeutics. 8(1). 30–37. 28 indexed citations
13.
Huhtikangas, Aarre, et al.. (1982). Application of Radioimmunoassay to the Quantitation of Hyoscyamine in Plant Material. Planta Medica. 45(8). 237–239. 10 indexed citations
14.
Jaup, B. H., Hasse Abrahamsson, R Virtanen, & E Iisalo. (1982). Effect of Pirenzepine Compared with Atropine and L-Hyoscyamine on Esophageal Peristaltic Activity in Humans. Scandinavian Journal of Gastroenterology. 17(2). 233–239. 17 indexed citations
15.
Virtanen, R, E Iisalo, & Kerttu Irjala. (1982). Protein Binding of Doxepin and Desmethyldoxepin. Acta Pharmacologica et Toxicologica. 51(2). 159–164. 9 indexed citations
16.
Virtanen, R, et al.. (1982). Pharmacokinetic Studies on Atropine with Special Reference to Age. Acta Anaesthesiologica Scandinavica. 26(4). 297–300. 40 indexed citations
17.
Virtanen, R. (1981). Excretion of nortriptyline into saliva.. PubMed. 19(2). 78–81. 2 indexed citations
18.
Kanto, J, et al.. (1981). Placental Transfer and Pharmacokinetics of Atropine after a Single Maternal Intravenous and Intramuscular Administration. Acta Anaesthesiologica Scandinavica. 25(2). 85–88. 34 indexed citations
19.
Virtanen, R, Mika Scheinin, & E Iisalo. (1980). Single Dose Pharmacokinetics of Doxepin in Healthy Volunteers. Acta Pharmacologica et Toxicologica. 47(5). 371–376. 23 indexed citations
20.
Virtanen, R, J Kanto, & E Iisalo. (1980). Radioimmunoassay for Atropine and l‐Hyoscyamine. Acta Pharmacologica et Toxicologica. 47(3). 208–212. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026